Haffner S M, Morales P A, Stern M P, Gruber M K
Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7873.
Diabetes. 1992 Oct;41(10):1267-72. doi: 10.2337/diab.41.10.1267.
NIDDM patients have a two- to fourfold increased risk of CHD relative to nondiabetic subjects. This excess risk is explained only partially by increased levels of standard risk factors. We compared the plasma concentrations of Lp(a) in NIDDM patients (n = 260) and nondiabetic subjects (n = 336) who participated in a population-based study (San Antonio Heart Study). Lp(a) was measured using a monoclonal anti-Lp(a) antibody. NIDDM patients and nondiabetic subjects had similar Lp(a) concentrations for both men (13.6 +/- 1.5 vs. 16.1 +/- 1.4 mg/dl) and women (12.6 +/- 0.8 vs. 15.9 +/- 1.3 mg/dl) (P = 0.361). Duration of diabetes and level of fasting glycemia were not significantly related to Lp(a) concentrations. Lp(a) levels were significantly higher in patients who had higher total and LDL cholesterol levels. We conclude that in a large population-based study, Lp(a) levels are not increased in NIDDM patients.
与非糖尿病患者相比，2型糖尿病（NIDDM）患者患冠心病（CHD）的风险增加了两到四倍。这种额外的风险仅部分由标准风险因素水平的升高来解释。我们比较了参与一项基于人群的研究（圣安东尼奥心脏研究）的260例NIDDM患者和336例非糖尿病患者的血浆脂蛋白（a）[Lp（a）]浓度。使用抗Lp（a）单克隆抗体测量Lp（a）。NIDDM患者和非糖尿病患者的男性Lp（a）浓度相似（13.6±1.5对16.1±1.4mg/dl），女性也相似（12.6±0.8对15.9±1.3mg/dl）（P = 0.361）。糖尿病病程和空腹血糖水平与Lp（a）浓度无显著相关性。总胆固醇和低密度脂蛋白胆固醇水平较高的患者Lp（a）水平显著更高。我们得出结论，在一项大型基于人群的研究中，NIDDM患者的Lp（a）水平没有升高。
